

**NCIC CLINICAL TRIALS GROUP - GI DISEASE SITE COMMITTEE**

**PANCREAS  
DISEASE ORIENTED GROUP**

AGENDA

**OPEN SESSION**

Venue: Rossetti Room, Delta Chelsea Hotel, Toronto

Date: Saturday, April 28<sup>th</sup>, 2012

Time: 08:00 to 08:45 hrs

Chairs: Dr. Malcolm Moore & Dr. Steve Gallinger

08:00 WELCOME AND INTRODUCTION / MEMBERSHIP UPDATE Dr. D. Jonker

08:00 – 08:40 TRIALS/CONCEPTS IN DEVELOPMENT/PROCESS

A Randomized Crossover Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination with Gemcitabine Compared with Gemcitabine Alone in Previously Untreated Patients with Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma: Results and Discussion of Next Steps

Drs T. Pearce and I. Melezínek

**PA.6 (ACCORD 24):** Randomized multicenter phase III comparison of adjuvant chemotherapy with gemcitabine versus a combination of 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) in patients with resected pancreatic adenocarcinoma

Drs J. Biagi & A. Wei

08:40 – 08:45 INTERGROUP TASK FORCE UPDATE

08:45 CLOSING REMARKS